Geographic variation in heart failure with reduced ejection fraction: insights from the VICTORIA trial

Abstract Background Geographic differences and background therapy have not been explored in the global VICTORIA trial, which enrolled high-risk patients with recent worsening heart failure reduced ejection fraction (HFrEF). Methods results Among 5050 5 pre-specified geographic regions, 34% were from Eastern Europe, 18% Western 23% Asia Pacific, 14% Latin South America, 11% North America (Table 1). Patients Europe older, had more atrial fibrillation, lower glomerular filtration rates. coronary artery disease exhibited advanced symptoms (∼50% New York Heart Association [NYHA] class III), whereas those less symptomatic (∼70% NYHA II). American largest body mass index as well diabetes hypertension. Levels of NT-proBNP at randomization MAGGIC risk scores highest European patients. Evidence-based triple medication was used most frequently America; conversely, cardiac resynchronization implantable cardioverter defibrillators least America. The overall primary composite event rate (cardiovascular death or HF hospitalization) placebo arm 36.6/100 person-years over a median 10.8 months after adjusting for score. When examined by region, these rates nominally lowest Europe. Conclusion Substantial regional exist characteristics treatments among this trial HFrEF event. These findings demonstrate continuing unmet needs opportunities enhancing care HFrEF. Funding Acknowledgement Type funding sources: Private company. Main source(s): funded Merck Sharp & Dohme Corp., subsidiary Co., Inc., Kenilworth, NJ, USA Bayer AG, Wuppertal, Germany.